title: Rituximab Treatment of Nivolumab-Induced Bullous Pemphigoid.
authors.affiliation: The Center for Cutaneous Oncology, Department of Dermatology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, Massachusetts.
authors.forename: Laura
authors.initials: L
authors.lastname: Sowerby
authors.affiliation: The Center for Cutaneous Oncology, Department of Dermatology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, Massachusetts.
authors.forename: Anna K
authors.initials: AK
authors.lastname: Dewan
authors.affiliation: Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts.
authors.forename: Scott
authors.initials: S
authors.lastname: Granter
authors.affiliation: The Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
authors.forename: Leena
authors.initials: L
authors.lastname: Gandhi
authors.affiliation: The Center for Cutaneous Oncology, Department of Dermatology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, Massachusetts.
authors.forename: Nicole R
authors.initials: NR
authors.lastname: LeBoeuf
mesh_terms: D000369:Aged, 80 and over; D000074322:Antineoplastic Agents, Immunological / Q000009:adverse effects / Q000627:therapeutic use; D001706:Biopsy; D005500:Follow-Up Studies; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D008175:Lung Neoplasms / Q000188:drug therapy; D008297:Male; D000077594:Nivolumab / Q000009:adverse effects* / Q000627:therapeutic use; D010391:Pemphigoid, Bullous / Q000139:chemically induced / Q000175:diagnosis / Q000188:drug therapy*; D000069283:Rituximab / Q000627:therapeutic use*; D012867:Skin / Q000187:drug effects / Q000473:pathology*
chemical_list: D000074322:Antineoplastic Agents, Immunological; D007155:Immunologic Factors; D000077594:Nivolumab; D000069283:Rituximab